Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

Leukemia. 2018 Jul 20. doi: 10.1038/s41375-018-0210-1. [Epub ahead of print]

PMID:
30030507
2.

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.

Fouquet G, Guidez S, Richez V, Stoppa AM, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T, Sabirou F, Levy A, Franques P, Gardeney H, Karlin L, Benboubker L, Ouali M, Vedovato JC, Ferre P, Pavlyuk M, Attal M, Facon T, Leleu X.

Oncotarget. 2018 May 8;9(35):23890-23899. doi: 10.18632/oncotarget.25156. eCollection 2018 May 8.

3.

Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes.

Filliatre-Clement L, Maucort-Boulch D, Bourbon E, Karlin L, Safar V, Bachy E, Sesques P, Ferrant E, Bouafia F, Lazareth A, Ghergus D, Coiffier B, Traverse Glehen A, Salles G, Ghesquieres H, Sarkozy C.

Hematol Oncol. 2018 May 2. doi: 10.1002/hon.2512. [Epub ahead of print]

PMID:
29722049
4.

Real life management of patients hospitalized with multiple myeloma in France.

Dumontet C, Couray-Targe S, Teisseire M, Karlin L, Maucort-Boulch D.

PLoS One. 2018 May 1;13(5):e0196596. doi: 10.1371/journal.pone.0196596. eCollection 2018.

5.

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.

Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, Marie D, André P, Paturel C, Zerbib R, Bennouna J, Salles G, Gonçalves A.

Oncotarget. 2018 Apr 3;9(25):17675-17688. doi: 10.18632/oncotarget.24832. eCollection 2018 Apr 3.

6.

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.

Besson L, Charrier E, Karlin L, Allatif O, Marçais A, Rouzaire P, Belmont L, Attal M, Lombard C, Salles G, Walzer T, Viel S.

Front Immunol. 2018 Apr 13;9:704. doi: 10.3389/fimmu.2018.00704. eCollection 2018.

7.

Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC.

Augeul-Meunier K, Chretien ML, Stoppa AM, Karlin L, Benboubker L, Diaz JMT, Mohty M, Yakoub-Agha I, Bay JO, Perrot A, Bulabois CE, Huynh A, Mercier M, Frenzel L, Avet-Loiseau H, de Latour RP, Cornillon J.

Bone Marrow Transplant. 2018 Jun;53(6):749-755. doi: 10.1038/s41409-018-0122-8. Epub 2018 Mar 9.

PMID:
29523884
8.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Fouquet G, Karlin L, Macro M, Caillot D, Roussel M, Arnulf B, Pegourie B, Petillon MO, Mathiot C, Hulin C, Kolb B, Stoppa AM, Brechiniac S, Rodon P, Dib M, Tiab M, Richez V, Araujo C, Wetterwald M, Garderet L, Royer B, Perrot A, Benboubker L, Decaux O, Escoffre-Barbe M, Fermand JP, Moreau P, Avet-Loiseau H, Attal M, Facon T, Leleu X.

Ann Hematol. 2018 May;97(5):831-837. doi: 10.1007/s00277-018-3236-6. Epub 2018 Jan 12.

PMID:
29330561
9.

Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.

Mohty M, Azar N, Chabannon C, Le Gouill S, Karlin L, Farina L, Milkovich G, Ostermann H, Glaß B, Noppeney R, Kron F, Kron A, Hübel K.

Bone Marrow Transplant. 2018 Mar;53(3):246-254. doi: 10.1038/s41409-017-0033-0. Epub 2017 Dec 18.

PMID:
29255168
10.

Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.

Sens F, Chaintreuil D, Jolivot A, Guebre-Egziabher F, Robinson P, Karlin L, Bridoux F, Juillard L.

Am J Nephrol. 2017;46(5):355-363. doi: 10.1159/000481461. Epub 2017 Oct 10.

PMID:
29017155
11.

Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?

Ranchon F, Vantard N, Henin E, Bachy E, Sarkozy C, Karlin L, Bouafia-Sauvy F, Gouraud A, Schwiertz V, Bourbon E, Baudouin A, Caffin AG, Vial T, Salles G, Rioufol C.

Hematol Oncol. 2018 Apr;36(2):399-406. doi: 10.1002/hon.2479. Epub 2017 Oct 6.

PMID:
28983943
12.

Initial Cast Correction as a Predictor of Treatment Outcome Success for Infantile Idiopathic Scoliosis.

Gomez JA, Grzywna A, Miller PE, Karlin LI, Garg S, Sanders JO, Sturm PF, Sponseller PD, D'Astous JL, Glotzbecker MP; Children’s Spine Study Group; Growing Spine Study Group.

J Pediatr Orthop. 2017 Dec;37(8):e625-e630. doi: 10.1097/BPO.0000000000001006.

PMID:
28834850
13.

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.

Fouquet G, Snell KI, Guidez S, Schraen S, Boyle E, Renaud L, Desmier D, Machet A, Moya N, Systchenko T, Gruchet C, Decaux O, Arnulf B, Fohrer C, Richez V, Kolb B, Macro M, Karlin L, Royer B, Pegourie B, Hebraud B, Caillot D, Perrot A, Moreau P, Facon T, Avet-Loiseau H, Dejoie T, Hulin C, Harding S, Leleu X.

Leuk Lymphoma. 2018 Mar;59(3):583-589. doi: 10.1080/10428194.2017.1339876. Epub 2017 Jul 12.

PMID:
28697637
14.

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F.

J Clin Oncol. 2017 Sep 1;35(25):2911-2918. doi: 10.1200/JCO.2017.72.2975. Epub 2017 Jul 7.

PMID:
28686535
15.

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.

Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, Salles G, Dyer MJS.

Blood. 2017 May 18;129(20):2808-2810. doi: 10.1182/blood-2017-02-765115. Epub 2017 Apr 4. No abstract available.

16.

Sagittal plane parameters in growing rod patients following final fusion.

Murphy RF, Emans JB, Troy M, Miller PE, Hresko MT, Karlin LI, Hedequist DJ, Glotzbecker MP.

J Pediatr Orthop B. 2018 Mar;27(2):168-175. doi: 10.1097/BPB.0000000000000446.

PMID:
28328741
17.

Staged Growing Rods With Preimplantation of Spinal Anchors for Complex Early Onset Scoliosis.

Gomez JA, Grzywna A, Hanstein R, Emans JB, Hresko MT, Hedequist D, Karlin LI, Glotzbecker MP.

J Pediatr Orthop. 2017 Dec;37(8):e606-e611. doi: 10.1097/BPO.0000000000000957.

PMID:
28244928
18.

The surgical treatment of spinal deformity in children with myelomeningocele: the role of personalized three-dimensional printed models.

Karlin L, Weinstock P, Hedequist D, Prabhu SP.

J Pediatr Orthop B. 2017 Jul;26(4):375-382. doi: 10.1097/BPB.0000000000000411.

PMID:
27902634
19.

Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.

Garderet L, Beohou E, Caillot D, Stoppa AM, Touzeau C, Chretien ML, Karlin L, Moreau P, Fontan J, Blaise D, Polge E, Gueye MS, Ikhlef S, Marjanovic Z, Labopin M, Mohty M.

Haematologica. 2016 Nov;101(11):1390-1397. Epub 2016 Sep 9.

20.

Efficacy of Intraoperative Neurophysiologic Monitoring for Pediatric Cervical Spine Surgery.

Tobert DG, Glotzbecker MP, Hresko MT, Karlin LI, Proctor MR, Emans JB, Miller PE, Hedequist DJ.

Spine (Phila Pa 1976). 2017 Jul 1;42(13):974-978. doi: 10.1097/BRS.0000000000001952.

PMID:
27792108
21.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, Boyle E, Chretien ML, Fontan J, Belhadj K, Brechignac S, Decaux O, Voillat L, Rodon P, Fitoussi O, Araujo C, Benboubker L, Fontan C, Tiab M, Godmer P, Luycx O, Allangba O, Pignon JM, Fuzibet JG, Legros L, Stoppa AM, Dib M, Pegourie B, Orsini-Piocelle F, Karlin L, Arnulf B, Roussel M, Garderet L, Mohty M, Meuleman N, Doyen C, Lenain P, Macro M, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H.

Blood. 2016 Dec 22;128(25):2941-2948. doi: 10.1182/blood-2016-07-726778. Epub 2016 Oct 11.

22.

European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.

Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau ME, d'Amore F, Haioun C, Thieblemont C, González-Barca E, García CG, Johnson PW, van Imhoff GW, Ng T, Dwyer K, Morschhauser F.

Haematologica. 2016 Oct;101(10):e407-e410. Epub 2016 Jul 14. No abstract available.

23.

Multiple myeloma: patient outcomes in real-world practice.

Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M.

Br J Haematol. 2016 Oct;175(2):252-264. doi: 10.1111/bjh.14213. Epub 2016 Jul 13.

24.

Multiple myeloma: practice patterns across Europe.

Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Schoen P, Yong K.

Br J Haematol. 2016 Oct;175(1):66-76. doi: 10.1111/bjh.14193. Epub 2016 Jun 13.

PMID:
27291397
25.

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP.

J Clin Oncol. 2016 Jun 20;34(18):2125-32. doi: 10.1200/JCO.2015.63.1929. Epub 2016 Apr 25.

PMID:
27114594
26.

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.

Weisel KC, Dimopoulos MA, Moreau P, Lacy MQ, Song KW, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Knop S, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel J.

Haematologica. 2016 Jul;101(7):872-8. doi: 10.3324/haematol.2015.137083. Epub 2016 Apr 14.

27.

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.

Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, Salles G, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C.

Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18.

PMID:
27063978
28.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Fouquet G, Pegourie B, Macro M, Petillon MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G, Kolb B, Stoppa AM, Brechiniac S, Richez V, Rodon P, Banos A, Wetterwald M, Garderet L, Royer B, Hulin C, Benbouker L, Decaux O, Escoffre-Barbe M, Fermand JP, Attal M, Avet-Loiseau H, Moreau P, Facon T, Leleu X; IFM (Intergroupe Francophone du Myélome).

Ann Oncol. 2016 May;27(5):902-7. doi: 10.1093/annonc/mdw017. Epub 2016 Jan 19.

29.

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.

Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T.

Haematologica. 2016 Mar;101(3):363-70. doi: 10.3324/haematol.2015.133629. Epub 2015 Dec 11.

30.

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G.

Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5.

31.

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E, Hulin C, Leleu X, Orsini-Piocelle F, Blade JS, Sohn C, Karlin L, Delbrel X, Hebraud B, Roussel M, Marit G, Garderet L, Mohty M, Rodon P, Voillat L, Royer B, Jaccard A, Belhadj K, Fontan J, Caillot D, Stoppa AM, Attal M, Facon T, Moreau P, Minvielle S, Avet-Loiseau H.

Blood. 2015 Dec 17;126(25):2713-9. doi: 10.1182/blood-2015-06-650242. Epub 2015 Oct 29.

32.

Lenalidomide is safe and active in Waldenström macroglobulinemia.

Fouquet G, Guidez S, Petillon MO, Louni C, Ohyba B, Dib M, Poulain S, Herbaux C, Martin A, Thielemans B, Brice P, Choquet S, Bakala J, Bories C, Demarquette H, Nudel M, Tournilhac O, Arnulf B, LeGouill S, Morel P, Banos A, Karlin L, Salles G, Leblond V, Leleu X.

Am J Hematol. 2015 Nov;90(11):1055-9. doi: 10.1002/ajh.24175. Epub 2015 Oct 6.

33.

[Pomalidomide for multiple myeloma].

Fouquet G, Macro M, Decaux O, Fohrer C, Guidez S, Demarquette H, Le Grand C, Prodhomme C, Renaud L, Bories C, Herbaux C, Karlin L, Roussel M, Benboubker L, Hulin C, Arnulf B, Leleu X.

Rev Med Interne. 2015 Sep;36(9):613-8. doi: 10.1016/j.revmed.2015.04.007. Epub 2015 Aug 6. Review. French.

PMID:
26257103
34.

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF.

Haematologica. 2015 Oct;100(10):1327-33. doi: 10.3324/haematol.2014.117077. Epub 2015 Aug 6.

35.

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Lazareth A, Song XY, Coquin A, Harel S, Karlin L, Belhadj K, Roos-Weil D, Frenzel L, Tamburini J, Macro M, Chevret S, Loiseau HA, Minvielle S, Fermand JP, Soulier J, Bories JC, Arnulf B.

Haematologica. 2015 Nov;100(11):e471-4. doi: 10.3324/haematol.2015.127001. Epub 2015 Jul 23. No abstract available.

36.

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Renner C, Bahlis NJ, Yu X, Teasdale T, Sternas L, Jacques C, Zaki MH, Dimopoulos MA.

Haematologica. 2015 Oct;100(10):1334-9. doi: 10.3324/haematol.2015.125864. Epub 2015 Jul 9.

37.

Ofatumumab in the treatment of non-Hodgkin's lymphomas.

Karlin L, Coiffier B.

Expert Opin Biol Ther. 2015 Jul;15(7):1085-91. doi: 10.1517/14712598.2015.1055241. Epub 2015 Jun 4. Review.

PMID:
26043777
38.

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.

Hebraud B, Magrangeas F, Cleynen A, Lauwers-Cances V, Chretien ML, Hulin C, Leleu X, Yon E, Marit G, Karlin L, Roussel M, Stoppa AM, Belhadj K, Voillat L, Garderet L, Macro M, Caillot D, Mohty M, Facon T, Moreau P, Attal M, Munshi N, Corre J, Minvielle S, Avet-Loiseau H.

Blood. 2015 Mar 26;125(13):2095-100. doi: 10.1182/blood-2014-07-587964. Epub 2015 Jan 30.

39.

Spinal deformity progression after posterior segmental instrumentation and fusion for idiopathic scoliosis.

Upasani VV, Hedequist DJ, Hresko MT, Karlin LI, Emans JB, Glotzbecker MP.

J Child Orthop. 2015 Feb;9(1):29-37. doi: 10.1007/s11832-015-0632-5. Epub 2015 Jan 20.

40.

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome (IFM).

Blood. 2015 Feb 26;125(9):1411-7. doi: 10.1182/blood-2014-11-612069. Epub 2015 Jan 9.

41.

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.

Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, Corre J.

Haematologica. 2014 Jul;99(7):1236-8. doi: 10.3324/haematol.2013.098608. Epub 2014 Apr 11.

42.

The changing landscape of peripheral T-cell lymphoma in the era of novel therapies.

Karlin L, Coiffier B.

Semin Hematol. 2014 Jan;51(1):25-34. doi: 10.1053/j.seminhematol.2013.11.001. Epub 2013 Nov 14. Review.

PMID:
24468313
43.

Gain in spinal height from surgical correction of idiopathic scoliosis.

Spencer HT, Gold ME, Karlin LI, Hedequist DJ, Hresko MT.

J Bone Joint Surg Am. 2014 Jan 1;96(1):59-65. doi: 10.2106/JBJS.L.01333.

PMID:
24382726
44.

Monitoring NK cell activity in patients with hematological malignancies.

Viel S, Charrier E, Marçais A, Rouzaire P, Bienvenu J, Karlin L, Salles G, Walzer T.

Oncoimmunology. 2013 Sep 1;2(9):e26011. Epub 2013 Sep 12. Review.

45.

Efficacy of nonfusion treatment for subacute and chronic atlanto-axial rotatory fixation in children.

Glotzbecker MP, Wasser AM, Hresko MT, Karlin LI, Emans JB, Hedequist DJ.

J Pediatr Orthop. 2014 Jul-Aug;34(5):490-5. doi: 10.1097/BPO.0000000000000128.

PMID:
24276230
46.

Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.

Sarkozy C, Baseggio L, Feugier P, Callet-Bauchu E, Karlin L, Seymour JF, Lebras L, Michallet AS, Offner F, Dumas O, Traverse-Glehen A, Ffrench M, Lopez-Guillermo A, Berger F, Coiffier B, Felman P, Salles G.

Br J Haematol. 2014 Mar;164(5):659-67. doi: 10.1111/bjh.12675. Epub 2013 Nov 26.

PMID:
24274024
47.

Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management.

Rossi C, Brisou G, Baseggio L, Roch J, Safar V, Karlin L, Sesques P, Bouafia-Sauvy F, Lebras L, Coiffier B, Salles G, Michallet AS.

Leuk Lymphoma. 2014 Aug;55(8):1939-41. doi: 10.3109/10428194.2013.858152. Epub 2014 Jan 28. No abstract available.

PMID:
24237449
48.

Proximal Junctional Kyphosis After Vertical Expandable Prosthetic Titanium Rib Insertion.

Li Y, Gold M, Karlin L.

Spine Deform. 2013 Nov;1(6):425-433. doi: 10.1016/j.jspd.2013.07.013. Epub 2013 Nov 21.

PMID:
27927368
49.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M.

Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.

PMID:
24007748
50.

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, Karlin L, Hulin C, Gentil C, Guilhot F, Garderet L, Lamy T, Brechignac S, Pegourie B, Jaubert J, Dib M, Stoppa AM, Sebban C, Fohrer C, Fontan J, Fruchart C, Macro M, Orsini-Piocelle F, Lepeu G, Sohn C, Corre J, Facon T, Moreau P, Attal M, Avet-Loiseau H.

Leukemia. 2014 Mar;28(3):675-9. doi: 10.1038/leu.2013.225. Epub 2013 Jul 29.

PMID:
23892719

Supplemental Content

Loading ...
Support Center